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Abstract
Aims: We examined, in a country of the African region, i) the prevalence of the metabolic
syndrome (MetS) according to three definitions (ATP, WHO and IDF); ii) the distribution of the
MetS criteria; iii) the level of agreement between these three definitions and iv) we also examined
these issues upon exclusion of people with diabetes.
Methods:  We conducted an examination survey on a sample representative of the general
population aged 25–64 years in the Seychelles (Indian Ocean, African region), attended by 1255
participants (participation rate of 80.3%).
Results: The prevalence of MetS increased markedly with age. According to the ATP, WHO and
IDF definitions, the prevalence of MetS was, respectively, 24.0%, 25.0%, 25.1% in men and 32.2%,
24.6%, 35.4% in women. Approximately 80% of participants with diabetes also had MetS and the
prevalence of MetS was approximately 7% lower upon exclusion of diabetic individuals. High blood
pressure and adiposity were the criteria found most frequently among MetS holders irrespective
of the MetS definitions. Among people with MetS based on any of the three definitions, 78% met
both ATP and IDF criteria, 67% both WHO and IDF criteria, 54% both WHO and ATP criteria and
only 37% met all three definitions.
Conclusion:  We identified a high prevalence of MetS in this population in epidemiological
transition. The prevalence of MetS decreased by approximately 32% upon exclusion of persons
with diabetes. Because of limited agreement between the MetS definitions, the fairly similar
proportions of MetS based on any of the three MetS definitions classified, to a substantial extent,
different subjects as having MetS.
Introduction
The metabolic syndrome (MetS) represents a cluster of
metabolic risk factors that co-occur to a greater degree
than predicted by chance. While it is clear that MetS is
associated with cardiovascular disease and diabetes [1], it
is still controversial whether MetS adds predictive value
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that goes beyond that of its single constituents [1,2]. Insu-
lin resistance was initially the main focus of MetS, but adi-
posity, sedentary lifestyle, dietary and genetic factors have
also received much attention when considering the patho-
genesis of MetS [3]. High prevalence of MetS has often
been documented in developed countries and increas-
ingly so in developing countries [4-17], although data in
developing countries and particularly in the Sub-Saharan
region remain scarce [18].
Over the past decade, several definitions of MetS have
been coined. In this paper, we consider three major defi-
nitions: i) the definition of the World Health Organiza-
tion (WHO), issued in 1998 [19]; ii) the definition of the
National Cholesterol Education Program Adult Treatment
Panel III (ATP), issued in 2001 and updated in 2004 and
2005 [20], and the definition of the International Diabe-
tes Federation (IDF), introduced in 2005 [21]. These defi-
nitions agree that the core criteria of MetS include: i)
blood glucose impairment (hyperglycemia and/or insulin
resistance), ii) excess abdominal/body fat (increased waist
and/or obesity), iii) dyslipidemia (low HDL-cholesterol
and/or high triglycerides), and iv) elevated blood pres-
sure. However, criteria and cut-off values differ between
these definitions, implying that different definitions may
identify different people, as documented in the few stud-
ies that have addressed this question [4,7,8,22].
There is some controversy over whether identification of
MetS should exclude people with diabetes since diabetes
alone is sufficient to define high cardiovascular risk and
MetS has been used as a tool to predict diabetes [2,23].
This analysis had four main objectives. First, we evaluated
the prevalence of MetS according to three MetS definitions
in the Seychelles, a rapidly developing country of the Afri-
can region. Second, we examined the distribution of the
MetS criteria according to the different MetS definitions.
Third, we compared the level of agreement between the
different MetS definitions and their ability to identify the
same subjects. Fourth, we examined how the prevalence
of MetS and the other end points differed upon restricting
assessment of the metabolic syndrome to the non-dia-
betic population.
Methods
Survey procedures
The Republic of Seychelles is a group of islands in the
Indian Ocean (African region) situated approximately
1800 km east of Kenya. A large majority of the population
is of African descent. HIV and cardiovascular diseases
account for approximately 1% and 38% of total mortality,
respectively [24]. High prevalence of several cardiovascu-
lar risk factors including obesity, hypertension and diabe-
tes has been documented as early as in 1989 [25] and in
2004 [26-28].
A population-based survey of cardiovascular risk factors
was conducted in 2004 under the auspices of the Ministry
of Health of the Republic of Seychelles (Seychelles Heart
Study III). Methods and main results have been published
previously [26-28]. Briefly, the sampling frame consisted
of a sex and age stratified random sample of the entire
population aged 25–64 years. Eligible participants were
selected from computerized data of a national population
census in 2002, thereafter updated by the civil status
authorities. The survey was approved by the Ministry of
Health after technical and ethical reviews. Eligible partici-
pants were invited by a letter to attend the survey at study
centers on specified dates. They were free to participate
and gave written informed consent.
Blood pressure was defined as the average of the last two
of three measurements with a mercury sphygmomanom-
eter taken at intervals longer than 2 minutes after the par-
ticipants had been sitting for at least 30 minutes. Weight
was measured with precision electronic scales (Seca, Ham-
burg) and height was measured with a fixed stadiometer.
Fasting blood was taken between 7:00 and 10:00 am.
Serum was obtained within 2 hours of blood collection
and immediately frozen to -20°C. Blood lipids were
measured with standard methods. Fasting blood glucose
(FBG) was analyzed immediately with a point-of-care
analyzer (Cholestec LDX, Hayward, USA). If glucose was
≥ 5.6 mmol/l and the participant was not aware of having
diabetes, an additional capillary measurement was per-
formed within 10 minutes with a glucometer that adjusts
readings to plasma values (Ascencia Elite, Bayer) and the
average of the two readings was considered [27]. An oral
glucose tolerance test (OGTT) was performed on all peo-
ple who had FBG between 5.6 and 7.0 mmol/L but had
never been diagnosed with diabetes. Fasting serum insulin
was measured using commercial RIA kits (LINCO
Research Inc, Missouri, USA). Microalbuminuria was
measured with a semi-quantitative method using a Cli-
nitek Status analyzer (Bayer, Leverkussen, Germany) [28].
Definitions of the metabolic syndrome
The prevalence of MetS was calculated according to the
standard criteria detailed in Table 1. For the WHO defini-
tion, we defined insulin resistance as the upper quartile of
the homeostasis model assessment of insulin resistance
(HOMA-IR), calculated as [fasting serum insulin level
(microU/ml) × fasting blood glucose level (mmol/L)]/
22.5 [29], which has been shown to be a reliable estimate
of insulin resistance both among diabetic and non dia-
betic subjects [30,31]. For the IDF definition, we used eth-
nic-specific cutoff values for waist circumference, i.e. theCardiovascular Diabetology 2008, 7:27 http://www.cardiab.com/content/7/1/27
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same criteria for Europid and Sub-Saharan subjects (≥ 94
cm for men and ≥ 80 cm for women) [21] and, by exten-
sion, for people of 'mixed' descent, and ≥ 90 cm for men
and ≥ 80 cm for women of the 4% of participants consid-
ered as 'Indian' or 'Chinese'. Information on treatment for
dyslipidemia was not available at an individual level and
we assumed that no one was under treatment, consistent
with the very low number of people treated in Seychelles
for dyslipidemia.
Analysis
Analysis was performed with Stata 9.0. All analyses were
standardized for age using the new WHO standard popu-
lation [32]. Agreement between the three MetS definitions
was determined using the Kappa statistic (κ). We graphed
Venn diagrams for agreement between different defini-
tions of MetS using the MATLAB 7.6 software, which
allows representing areas proportionally to the corre-
sponding numbers of cases. P values < 0.05 were consid-
ered statistically significant.
Results
Characteristics of the population
From the 1563 eligible participants, 1255 participated in
the survey (80.3% participation rate) and 1218 had all
necessary measurements to evaluate MetS according the
three considered definitions and were included in this
study. The distribution of selected risk factors and MetS
criteria is presented in Table 2.
Prevalence of the metabolic syndrome
Figure 1 shows the prevalence of MetS according to the
definitions by ATP, WHO and IDF. The age-standardized
prevalence of MetS in the population aged 25–64 years
was 28.1% (95% CI: 25.6–30.7), 24.8% (22.4–27.2) and
30.3% (27.7–32.9), respectively. At age 35–64, the age-
standardized prevalence was, respectively, 36.7% (33.6–
39.7), 32.4% (29.5–35.4) and 39% (35.9–42.1) overall;
31.9% (27.5–36.4), 33.4% (28.9–37.9) and 33.5%
(29.0–38.0) among men; and 41.4% (37.1–45.6), 31.4%
(27.5–35.4) and 44.4% (40.2–48.7), among women.
The prevalence of MetS increased markedly with age for
both genders. However, the prevalence of MetS using the
ATP definition was highest at age 45–54 for men. With
regards to gender, the prevalence was significantly greater
in women than in men according to the ATP and IDF def-
initions while the prevalence was similar in both genders
using the WHO definition.
A large proportion of people with diabetes also had MetS:
66.8%, 85.5%, 74% among men and 87.1%, 79.7%, 93%
among women, according to the ATP, WHO and IDF def-
initions, respectively. However, this proportion was
smaller among men at age 45–64 years than in the other
age categories (Figure 1).
Upon exclusion of individuals with diabetes, the age-
standardized prevalence of MetS at age 25–64 years was
Table 1: Criteria for three definitions of the metabolic syndrome (WHO, ATP, IDF)
WHO 1998 NCEP ATP III 2005 IDF 2005
Diabetes, IFG, IGT or insulin 
resistance1
plus two or more of the remaining 
criteria.
Any three or more criteria. Central obesity
plus two or more of the remaining 
criteria.
1. Adiposity Waist/hip ratio > 0.9 (M), > 0.85 (F) 
or BMI > 30 kg/m2
WC ≥ 102 cm (M), ≥ 88 cm (F) WC ≥ 94 cm (M), ≥ 80 cm (F)2
2. Raised blood pressure BP ≥ 140/90 mmHg or medication BP ≥ 130/85 mmHg or medication
3. Dyslipidemia TG ≥ 1.7 mmol/l or HDL < 0.9 mmol/
L (M), < 1.0 mmol/L (F)
TG ≥ 1.7 mmol/L or medication3
HDL-C < 1.03 mmol/L (M) or < 1.29 mmol/L (F) or medication3
4. Impaired glucose regulation 
(dysglycemia)
Diabetes, IFG (FBG ≥ 6.1 mmol/l), 
IGT, or insulin resistance1
FBG ≥ 5.6 mmol/L4 FBG ≥ 5.6 mmol/L or previously 
diagnosed diabetes
5. Microalbuminuria Microalbuminuria: albumin ≥ 20 μg/
min or albumin/creatinine ratio 
(ACR) ≥ 30 mg/g
WHO: World Health Organization [19]; ATP: National Cholesterol Education Program-Adult Treatment Panel III [20]; IDF: International Diabetes 
Federation [21].
BMI: body mass index; BP: blood pressure; HDL-C: high density lipoprotein cholesterol; FBG: fasting blood glucose; IFG: impaired fasting glucose; 
IGT: impaired glucose tolerance; TG: triglycerides; WC: waist circumference.
1 Glucose uptake below lowest quartile under hyperinsulinemic euglycemic conditions for background population under investigation.
2 Cut off for Sub Saharan Africans, Europids, and Eastern Mediterranean and Middle Eastern populations; ≥ 90 cm (M), ≥ 80 cm (F) for South Asians, 
Chinese, Japanese, and ethnic South and Central Americans [21].
3Specific treatment for hypertriglyceridemia or low HDL-cholesterol such as fibrate or nicotinic acid.
4This cut off was lowered from ≥ 6.1 mmol/L to ≥ 5.6 mmol/l in 2005 [20].Cardiovascular Diabetology 2008, 7:27 http://www.cardiab.com/content/7/1/27
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22.2% (19.6–24.7) according to ATP, 17.9% (15.6–20.2)
according to WHO and 23.8% (21.2–26.4) according to
IDF. Using the EGIR definition of MetS [33], a modified
version of the WHO definition that applies to non-dia-
betic subjects, the age-standardized prevalence of MetS
was 15.1% (95% CI: 12.9–17.3); 14.1% (10.9–17.2)
among men and 16.2% (13.1–19.2) among women.
Upon exclusion of persons with diabetes, the prevalence
(in absolute terms) of MetS decreased by 4.6%, 6.5%,
5.3% in men and 7.3%, 7.3%, 7.7% in women according
to the ATP, WHO and IDF definitions, respectively. This
corresponds to a relative decrease in the prevalence of
MetS of approximately 32%. At the age of 35–64 years, the
decrease in prevalence (in absolute terms) was respec-
tively 5.8%, 8.6%, 6.7% in men and 7.8%, 6.7%, 8.8% in
women (a relative decrease of approximately 34%). The
reduction in prevalence of MetS upon exclusion of sub-
jects with diabetes was slightly greater when using the
WHO definition of MetS than the other two definitions.
Distribution of criteria of the metabolic syndrome
High blood pressure, obesity and impaired glucose regu-
lation were the most prevalent criteria for all MetS defini-
tions (Figure 2). Hypertriglyceridemia was found more
often in men than in women, while the opposite was true
for low HDL-cholesterol. This criteria distribution was
similar across age categories.
Agreement between different definitions of the metabolic 
syndrome
Figure 3 shows the level of agreement between the three
MetS definitions. 37% of all subjects aged 25–64 had
MetS as based on any of the three MetS definitions.
Among these MetS-holders, 69% had MetS based on ATP
and IDF, 50% based on ATP and WHO, 53% based on
Table 2: Age-standardized distribution of selected risk factors in the population aged 25–64 years
All SD Men SD Women SD
N 1218 548 679
Age (years) 42.0 10.8 42.1 10.7 41.9 11.0
Anthropometric parameters
BMI (kg/m2) 26.9 5.7 25.5 4.7 28.3 6.3
Waist circumference (cm) 89.5 13.0 88.9 11.9 90.2 14.1
Adiposity ATP (%) WC ≥ 102 cm (M), ≥ 88 cm (W) 35.2 14.0 56.0
WHR > 0.9 (M), > 0.85 (W) or BMI 61.5 50.7 72.1
Adiposity WHO (%) > 30
Adiposity IDF (%) WC ≥ 94 cm (M), ≥ 80 cm (W) 55.8 35.8 75.6
Blood pressure
Systolic BP (mmHg) 127.7 18.6 131.0 17.7 124.4 18.8
Diastolic BP (mmHg) 83.3 11.8 85.5 11.7 81.2 11.5
Raised BP – ATP/IDF (%) BP ≥ 130/85 mmHg or medication 51.7 57.0 46.4
Raised BP – WHO (%) BP ≥ 140/90 mmHg or medication 39.5 43.3 35.7
Glucose regulation
Fasting glucose (mmol/L) 5.9 2.0 6.0 2.1 5.7 1.8
Insulin (pmol/L) 14.8 12.1 13.6 11.6 16.1 12.4
Impaired fasting glucose (%) 14.1 20.5 7.7
Impaired glucose tolerance (%) 12.6 13.9 11.2
Diabetes (%) 10.7 9.7 11.7
Dysglycemia ATP (%) FBG ≥ 5.6 mmol/l 33.3 40.0 26.7
Dysglycemia WHO (%) DM, IFG, IGT or insulin resistance 36.1 35.5 36.7
Dysglycemia IDF (%) FBG ≥ 5.6 mmol/l or history of DM 33.9 40.4 27.5
Blood lipids
Total cholesterol (mmol/L) 5.4 1.3 5.4 1.3 5.4 1.3
HDL cholesterol (mmol/L) 1.4 0.5 1.4 0.5 1.4 0.4
Triglyceride level (mmol/L) 1.0 0.8 1.2 1.0 0.9 0.5
Hypertriglyceridemia ATP/IDF (%) TG ≥ 1.7 mmol/l or medication 12.6 17.4 7.8
Low HDL-C ATP/IDF (%) HDLC < 1.03 (M); < 1.29 (W) 38.2 28.6 47.8
Dyslipidemia WHO (%) TG ≥ 1.7 or HDL < 0.9 (M), < 1.0 (W)) 23.8 27.3 20.3
Microalbuminuria 11.9 11.2 12.6
Regular cigarette smoking (%) 17.3 30.9 3.7
Alcohol (mL/day) 22.3 62.0 41.1 82.8 3.6 12.8
Mean ± SD (standard deviation) or proportion; BMI: body mass index; WC: waist circumference; WHR: waist to hip ratio; BP: blood pressure; DM: 
diabetes; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; M: men; W: women. HDL-cholesterol and triglyceride: units in mmol/L.Cardiovascular Diabetology 2008, 7:27 http://www.cardiab.com/content/7/1/27
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Prevalence of the metabolic syndrome according to sex, age category, diabetic status and different definitions of the metabolic  syndrome Figure 1
Prevalence of the metabolic syndrome according to sex, age category, diabetic status and different definitions 
of the metabolic syndrome.
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WHO and IDF; and 48% had MetS based on the three def-
initions. With reference to the total population, MetS was
diagnosed in 28% based on ATP, 25% based on WHO and
30% based on IDF. Based on Figure 3, one can calculate
that 25% were diagnosed with MetS based on ATP and
IDF, 20% based on WHO and IDF, 19% based on WHO
and ATP; and 18% based on all three definitions.
Within the non-diabetic population, 30% had MetS based
on either the WHO, ATP or IDF definitions, out of which
37% had MetS based on all three definitions.
The kappa statistic was 0.82 for ATP-IDF, 0.61 for IDF-
WHO and 0.59 for WHO-ATP, respectively 0.81, 0.53 and
0.51, upon exclusion of people with diabetes. The higher
kappa statistic for ATP-IDF versus either IDF-WHO or
WHO-ATP was found irrespective of gender and age
(Table 3).
In order to examine possible causes of fairly low agree-
ment between the MetS definitions, we compared agree-
ment between the criteria of the three MetS definitions in
the entire population (Table 4). The largest disagreement
was found for adiposity. As many as 70% of the total pop-
ulation fulfilled the criteria for adiposity according to
either the ATP, WHO or IDF definitions of MetS (i.e.
based on BMI, waist circumference or waist to hip ratio).
However, the prevalence of the adiposity criterion varied
largely according to the different MetS definitions: 35.2%
according to ATP, 61.5% according to WHO, and 55.8%
according to IDF. Out of those who qualified for adiposity
according to any MetS definitions, only 48% met all three
definitions. With regards to the other MetS criteria, the
WHO definition disagreed with the other two definitions
of MetS (ATP and IDF) in identifying people with dyslip-
idemia and to a lesser extent, with impaired glucose regu-
lation. However, these criteria are less prevalent in the
population than adiposity (Table 2), which results in less
impact on MetS classification.
Discussion
The main findings of the study are as follows: i) the prev-
alence of MetS was high in this population of East Africa
regardless of which MetS definition was used; ii) the prev-
alence of MetS decreased by approximately one third
upon exclusion of persons with diabetes; and iii) agree-
ment between different MetS definitions was limited and
consequently, the similar prevalence of MetS according to
either MetS definition actually identified, to a substantial
extent, different subjects as having MetS.
In our study, the prevalence of MetS at the age of 25–64
years ranged between 25% and 30%. This is much higher
than the 8% reported in Cameroon [18], which is, to the
best of our knowledge, the only other population based
published assessment of the prevalence of MetS in Sub-
Saharan Africa. A previous study in the Seychelles [34]
found that plasma aldosterone, but not plasma renin
activity, was associated with MetS. However this study
included participants from families with hypertension
and was therefore not intended to assess the prevalence of
MetS in the general population. In order to compare the
prevalence in Seychelles with that in other countries, we
compiled findings of selected population-based studies
that had assessed MetS according to at least two MetS def-
initions, and included participants of 35–64 years (Table
Proportion of subjects with the metabolic syndrome who have selected criteria according to sex and different definitions of the  metabolic syndrome (TG: triglyceride; HDL: HDL-cholesterol; BP: blood pressure) Figure 2
Proportion of subjects with the metabolic syndrome who have selected criteria according to sex and different 
definitions of the metabolic syndrome (TG: triglyceride; HDL: HDL-cholesterol; BP: blood pressure).
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5). The prevalence of MetS was similar in Seychelles as in
many Western countries [9-11,13] and in urban India
[15]. The prevalence of MetS in Seychelles was lower than
in certain countries, e.g. USA [5], Portugal [8], Samoa
[13], Turkey [7] and Tunisia [4] but higher than in Mexico
[6] and several Asian countries e.g. Korea [14], Japan [13]
and China [17]. The high prevalence of MetS in Seychelles
is consistent with high prevalence of several MetS criteria,
particularly overweight, hypertension, dyslipidemia and
diabetes [25-27].
The prevalence of MetS in Seychelles did not differ mark-
edly according to the three different MetS definitions, con-
sistent with observations in several populations
[5,9,10,14,17], but not in others [4-7,12,13]. However,
the prevalence of MetS in Seychelles was moderately
higher according to IDF than ATP or WHO, a finding
reported in most studies that had assessed this issue
[4,5,7,8,10-13,15], except for a few [16,17]. It has fre-
quently been reported that the prevalence of MetS accord-
ing to the WHO definition is generally greater among men
Agreement between three definitions of the metabolic syndrome (all prevalence estimates are expressed as percent of the  general population) Figure 3
Agreement between three definitions of the metabolic syndrome (all prevalence estimates are expressed as 
percent of the general population).
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than women [35] but we did not observe such a gender
difference in Seychelles.
The level of agreement between the different definitions
of MetS was not optimal in our study. Less than half of the
individuals labeled as having MetS according to any of the
three considered definitions were classified as MetS-hold-
ers according to all three definitions. We found that agree-
ment between the MetS definitions was better for IDF-ATP
than for WHO-IDF and WHO-ATP. This finding is consist-
ent with data in several populations on several continents
[7,8,10,13,15]. This difference is expected since MetS is
based on the same criteria according to IDF and ATP,
except for the adiposity criterion. Agreement between the
MetS definitions was generally better among women than
men in Seychelles, consistent with previous reports
[5,8,14]. This may relate to the fact, at least in Seychelles,
that the prevalence of the adiposity criterion was virtually
identical and close to 100% across the three MetS defini-
tions among women with MetS, but was lower and largely
different between MetS definitions in men.
Hence, we found a similar prevalence of MetS in Sey-
chelles according to the three different MetS definitions
but the different MetS definitions actually identified, to a
substantial extent, different individuals. Poor agreement
between MetS definitions has several clinical and epide-
miological implications [16,22]. First, it is questionable to
directly compare the burden of MetS between populations
based on different definitions. Second, it remains unclear
whether cardiometabolic outcomes differ if MetS is
defined according to one, two or three MetS definitions.
Few studies have assessed the predictive value of MetS
when MetS is based on more than one definition [36]. The
study of Benetos et al [36] showed that the prevalence of
MetS was markedly higher when MetS was based on either
the IDF or ATP (2005 version) definitions as compared to
the 2001 ATP definition alone, but only individuals with
MetS according to the 2001 ATP definition had a higher
risk of all-cause and cardiovascular mortality.
The prevalence of MetS restricted to the non-diabetic pop-
ulation (e.g. according to the EGIR definition, which is a
definition of MetS that explicitly excludes diabetes [33])
was similar in Seychelles as in several countries in Europe
[37-39] and higher than in Japan and Korea [13]. In the
Seychelles, about one third of the adults who had MetS
also had diabetes and, inversely, most adults who had dia-
betes also had MetS. Hence, the prevalence of MetS,
according to either the ATP, WHO and IDF definitions,
decreased markedly (a relative decrease of approximately
one third) upon exclusion of persons with diabetes. This
difference is larger than reported in other studies [6,13].
We also observed that this decrease in the prevalence of
MetS upon exclusion of diabetes was larger according to
the WHO definition compared to the ATP and IDF defini-
tions, which has also been observed in Samoa [13] and
Mexico [6].
The issue of whether MetS should be defined upon exclu-
sion of diabetes is relevant to both clinical practice and
epidemiology. It has been argued that MetS status does
not add incremental information for cardiovascular man-
agement of diabetic individuals [23], since diabetes alone
defines high cardiovascular risk. For the same reason, it
Table 3: Agreement (kappa values) between different definitions of the metabolic syndrome in the population with and without 
exclusion of diabetic persons
ATP-IDF IDF-WHO WHO-ATP
All Non-diabetic All Non-diabetic All Non-diabetic
All 0.82 0.81 0.61 0.53 0.59 0.51
Men 0.71 0.67 0.62 0.55 0.56 0.48
Women 0.92 0.91 0.60 0.52 0.63 0.53
Age 25–44 years 0.79 0.76 0.49 0.42 0.52 0.44
Age 45–64 years 0.83 0.83 0.64 0.58 0.58 0.53
Table 4: Kappa values between different criteria of different 
definitions of the metabolic syndrome
ATP-IDF IDF-WHO WHO-ATP
Total population
Obesity 0.60 0.55 0.44
Raised blood pressure 1.00 0.76 0.76
Impaired glucose regulation 0.99 0.67 0.66
Hypertriglyceridemia 1.00 1.00 1.00
Low HDL-cholesterol 1.00 0.50 0.50
Men
Obesity 0.45 0.55 0.27
Raised blood pressure 1.00 0.73 0.73
Impaired glucose regulation 0.99 0.65 0.64
Hypertriglyceridemia 1.00 1.00 1.00
Low HDL-cholesterol 1.00 0.69 0.69
Women
Obesity 0.58 0.45 0.50
Raised blood pressure 1.00 0.78 0.78
Impaired glucose regulation 0.98 0.70 0.68
Hypertriglyceridemia 1.00 1.00 1.00
Low HDL-cholesterol 1.00 0.36 0.36Cardiovascular Diabetology 2008, 7:27 http://www.cardiab.com/content/7/1/27
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has been suggested that the definition of MetS should
exclude individuals with known cardiovascular disease
[23]. The question of whether MetS should exclude diabe-
tes and/or cardiovascular disease is clearly dependent on
the expected purpose of MetS, i.e. whether MetS is used to
predict cardiovascular diseases, diabetes, insulin resist-
ance, or a combination of these conditions independent
of conventional risk factors. While our cross-sectional
study emphasizes that different definitions of MetS tend
to classify different individuals as having MetS, the most
important question remains to determine, based on lon-
gitudinal data, whether MetS predicts cardiovascular
events above the risk factors that constitute the syndrome.
Our study has some limitations. First, we cannot exclude
a healthy volunteer bias related to voluntary participation
to the study, which could tend to underestimate the actual
prevalence of MetS in the population. Second, we assessed
insulin resistance based on HOMA-IR, which is only par-
tially correlated with the gold standard (hyperinsulinemic
euglycemic clamp), yet a valid proxy for insulin resistance
[30,31]. Third, OGTT was only performed on participants
unaware of having diabetes and who had FBG between
5.6 and 7.0 mmol/l, hence a source of slight underestima-
tion of diabetes. On the other hand, strengths of the study
include the population-based design of the study, a fairly
large sample size, and a broad panel of investigations that
allowed us to directly compare the different MetS defini-
tions.
In conclusion, this study contributes to mapping the prev-
alence of MetS worldwide, particularly with regards to the
African region. The study also further contributes to the
longstanding debate regarding the significance of MetS.
The substantially different prevalence of MetS upon exclu-
sion of individuals with diabetes underlies the need to
clarify whether MetS is a tool for predicting cardiovascular
disease, diabetes, insulin resistance or any other risk con-
dition. These issues are further prompted by the finding,
in our study, that the different considered MetS defini-
tions identified, to a substantial extent, different individ-
uals. Not withstanding a much needed unified definition
of MetS, our findings in Seychelles emphasize the growing
burden of lifestyle-related non-communicable diseases in
countries in epidemiological transition including in the
African region, consistent with the ongoing epidemic of
obesity worldwide and in the Seychelles in particular.
List of abbreviations
ATP: National Cholesterol Education Program-Adult
Treatment Panel III; WHO: World Health Organization;
IDF: International Diabetes Federation; EGIR: European
Table 5: Prevalence of the metabolic syndrome in the Seychelles and in other populations, according to different definitions of the 
metabolic syndrome
ATP WHO IDF
Place Population Age n M W All M W All M W All
Africa
Seychelles Nation wide 25–64 1218 24 32 28 25 25 25 25 35 30
Tunisia [3] City of Tunis ≥ 40 863 15 31 24 26 31 29 30 56 46
Cameroon[17] City of Yaoundé and three rural villages 24–74 1573 < 0.5 < 0.2 - < 8 < 6 - < 2 < 2 -
Americas
USA [4] NHANES 1999–2002 ≥ 20 3601 34 35 35 - - - 41 37 39
Mexico [5] Nation wide 20–69 2158 29 25 27 13 14 14 - - -
Europe
Turkey [6] Istanbul (urban) and Kayseri (rural) > 20 1568 41 43 38 23 18 19 46 48 42
Portugal [7] City of Porto 18–92 1433 32 40 37 30 24 26 38 44 42
Canary Island [8] Nation wide > 30 1030 28 29 28 33 24 28 - - -
Norway [9] North-Trondelag Health Study (HUNT 2) 20–89 10,206 27 25 26 - - - 29 30 30
Germany [10] PROCAM study 16–65 7131 25 18 - - - - 32 23 -
Greece [11] Representative sample of Greek adults > 18 9,669 25 24 25 - - - - - 43
Asia
Samoa [12] Population-based (DETECT 2) > 35 1344 39 57 - 22 26 - 45 60 -
Australia [12] Population-based (DETECT 2) > 35 9409 36 28 - 26 18 - 42 33 -
Korea [13] Korean National Health and Nutrition Survey ≥ 20 6601 18 21 19 - - - 15 24 20
India [14] City of Chennai ≥ 20 2350 17 19 18 27 20 23 23 28 26
Taiwan [15] Taiwan National Nutrition and Health Survey ≥ 19 2608 12 17 - - - - 6 13 -
Japan [12] Population-based (DETECT 2) > 35 2016 8 10 - 3 3 - 8 11 -
China [16] Two agricultural counties 25–64 18,630 5 12 8 - - - 4 11 7
Men: men; W: women, ATP: National Cholesterol Education Program-Adult Treatment Panel III; WHO: World Health Organization, IDF: 
International Diabetes Federation.Cardiovascular Diabetology 2008, 7:27 http://www.cardiab.com/content/7/1/27
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Group for the Study of Insulin Resistance; HDL-choles-
terol: High density lipoprotein cholesterol; FBG: fasting
blood glucose; HOMA-IR: homeostasis model assessment
of insulin resistance; OGTT: oral glucose tolerance test.
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